Mersana Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN) has announced management presentations at two upcoming investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:15 p.m. ET, followed by the Baird 2022 Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET. A live webcast of the Morgan Stanley event will be available on Mersana's website, with a replay accessible for 90 days. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, notably its lead candidate, UpRi.

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at two upcoming investor conferences. Details are as follows:

Morgan Stanley 20th Annual Global Healthcare Conference
Format:	Fireside Chat
Date/Time:	Monday, September 12, 2022, at 4:15 p.m. Eastern Time
Baird 2022 Global Healthcare Conference
Format:	Fireside Chat
Date/Time:	Tuesday, September 13, 2022, at 2:00 p.m. Eastern Time

A live webcast of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors and Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

What is Mersana Therapeutics' upcoming event schedule in September 2022?

Mersana Therapeutics will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:15 p.m. ET and at the Baird 2022 Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET.

Where can I watch the Mersana Therapeutics conference presentations?

You can watch a live webcast of the Mersana Therapeutics presentation at the Morgan Stanley conference on their Investors & Media webpage.

What is Mersana Therapeutics' lead product candidate?

Mersana's lead product candidate is UpRi, a Dolaflexin ADC targeting NaPi2b, which is being studied in various clinical trials.

What is the focus of Mersana Therapeutics as a company?

Mersana Therapeutics is focused on discovering and developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.

How long will the live webcast archive be available after the event?

The archived replay of the live webcast will be available for approximately 90 days following the Morgan Stanley conference.